Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

lCept in the treatment of autoimmune indications and any future products for our targeting indications may be greater than anticipated; the risk that we may not sustain our profitability; our ability to attract and retain collaborations relating to the development and commercialization of new indications; competition from other pharmaceutical or biotechnology companies; our ability to raise additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; economic and capital market conditions; our ability to obtain and protect patents and other intellectual property rights; our ability to operate without infringing the intellectual property rights of others; our ability to comply with applicable governmental regulations and standards; currency exchange rates; and our ability to successfully attract and retain skilled and experienced personnel.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities regulatory authorities in Canada at http://www.sedar.com. Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of n
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today ... given the company permission to conduct an open-label study ... months of age with a diffuse intrinsic brainstem glioma ... five treatment groups based on their age and whether ... The primary study endpoint is a decrease in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of ... transformation in the pain market, according to a ... Inc., a firm providing market research and consultation ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... change for hydrocodone combination products from Schedule III ...
(Date:10/22/2014)... Oct. 22, 2014   Reproductive Medicine Associates ... in the field of infertility, presents new clinical ... screening. The research abstract, released during the 70 ... (ASRM) meeting in Honolulu, Hawaii ... gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... UPI ), a medical device company that develops, ... announced today that David Kaysen, President and CEO, and Medi ... strategy and financial results at the Sixth Annual JMP Securities ... 2011 at The St. Regis Hotel in New York. ...
... Reportlinker.com announces that a new market research report is ... The Global Market http://www.reportlinker.com/p0619259/Generic-Drugs-The-Global-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug ... The global generics market is estimated at about $225 ... the value of the total global generics sector will ...
Cached Medicine Technology:Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2Generic Drugs: The Global Market 2Generic Drugs: The Global Market 3Generic Drugs: The Global Market 4Generic Drugs: The Global Market 5Generic Drugs: The Global Market 6Generic Drugs: The Global Market 7Generic Drugs: The Global Market 8Generic Drugs: The Global Market 9Generic Drugs: The Global Market 10Generic Drugs: The Global Market 11Generic Drugs: The Global Market 12
(Date:10/25/2014)... 2014 Background: , In 1998 Bob ... is a pioneer in the field of establishing recovery community ... treatment system and when he retired, he set out to ... public service. , 1. Where are the ... them? , 2. Can the recovery community be organized ...
(Date:10/25/2014)... October 25, 2014 QueenBeeTickets.com has a ... great selection at affordable prices. Bob Seger & The ... Center and Nationwide Arena are going on sale October ... Click Here to browse the selection of tickets ... QueenBeeTickets.com. , The famous singer is touring North America ...
(Date:10/25/2014)... CT (PRWEB) October 25, 2014 Limbkeepers® ... upcoming episode of Innovations with Ed Begley Jr, airing ... times TBA. , In this episode, Innovations will focus ... helping to protect fragile, thinning skin on arms, hands, ... will learn about these versatile products, which help reduce ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Researchers who discovered ... findings are cause for concern. The use ... raised for human consumption contribute to the development ... to background information from the study. Each ... about 2 million people and kill about 23,000, ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... ... ‘Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery’. ... ... of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced ...
... fewer attacks per year, save millions in health costs, ... If all states banned smoking in restaurants, offices and ... from heart attacks would drop by more than 18,000 ... bans have been implemented in some states, but not ...
... explanation for the difference, study says , THURSDAY, May ... common form of stroke has decreased significantly among whites ... new regional survey designed to be representative of the ... Greater Cincinnati/Northern Kentucky Stroke Study showed an overall drop ...
... from The University of Texas MD Anderson Children,s Cancer Hospital ... patients increased the survival of children with rare tumors in ... issue of the Journal of Pediatric Surgery , looked ... aggressive pediatric cancer known as desmoplastic small round cell tumor ...
... Montreal, May 20, 2010 The results of a ... by Dr. Jean-Claude Tardif are now available in the journal ... of the MHI Research Centre, as well as a professor in ... at the Universit de Montral. The promising findings of ...
... ... Association (NRPA) is reminding Americans to take the proper steps to ensure that their local ... Dirty Dozen, a comprehensive brochure and playground-safety resource for playground managers, parents and caregivers. ... Ashburn, VA (Vocus) May ...
Cached Medicine News:Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 2Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 3Health News:Big Decline in Heart Attacks If All States Had Smoking Bans 2Health News:Stroke Incidence Down, But Not for Blacks 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 3Health News:Patients at high risk of recurrences of heart disease: Breakthrough in prevention 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: